Canada· CA-DIN-02228955
SUPREFACT DEPOT 2 MONTHS
A buserelin product containing buserelin (buserelin acetate), registered in Canada by CHEPLAPHARM ARZNEIMITTEL GMBH. The same ATC class is registered in 8 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Buserelin is registered in 8 of 19 countries.
Countries holding a registration under ATC L02AE01 (buserelin), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 4 of them publish a price we can compare per daily dose
Buserelin · ATC L02AE01
8 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Germany
- Icelandprice
- Italyprice
- Netherlands
- United Kingdom
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- BUSERELIN (BUSERELIN ACETATE)
- Manufacturer
- CHEPLAPHARM ARZNEIMITTEL GMBH
- Country
- Canada (CA)
- ATC code
- L02AE01
- ATC class
- Buserelin
- Defined daily dose
- 0.11 mg, Implantat
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Buserelin in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBusol vetaniMedica GmbH
- United KingdomBuserelin 5.5mg/5.5ml solution for injection vialsNeon Healthcare Ltd
- SwedenSuprecur 0,15 mg/dos Nässpray, lösningCheplapharm Arzneimittel GmbH
- ItalySUPREFACT*1 fiala SC 5,5 ml 1 mg/mlCHEPLAPHARM ARZNEIMITTEL GMBH
- SpainSUPREFACT 1 mg/ml SOLUCION INYECTABLECheplapharm Arzneimittel Gmbh
- GermanyMetrelefCheplapharm Arzneimittel Gmbh
- NetherlandsSuprefact Depot 3 maanden, implantatiestift 9,45 mgMedcor Pharmaceuticals B.V.
- BelgiumSuprefact Nasal 0.1 mgSanofi Belgium
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Austria · Suprecur, Suprefact
- Bulgaria · Супрефакт Депо 3 Месеца
- Germany · Profact Depot, Profact Pro Injectione
- Spain · Suprefact, Suprefact Depot
- United Kingdom (Northern Ireland) · Buserelin, Suprecur Injection
- Greece · Suprefact Depot 3 Μήνεσ
- Hungary · Suprefact
- Italy · Suprefact, Suprefact Depot
- Netherlands · Suprefact Depot
- Sweden · Suprecur, Suprefact
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ab3eb167-6edf-45d6-9134-60addb49f70b GET /v1/drugs/ab3eb167-6edf-45d6-9134-60addb49f70b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02228955",
"form": "IMPLANT",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L02AE01",
"schedule": [
"Prescription"
],
"drug_code": "43499",
"strengths": [
"6.3 MG"
],
"ahfs_class": null,
"substances": [
"BUSERELIN (BUSERELIN ACETATE)"
],
"product_categorization": null
}See everything about buserelin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.